between oral leukoplakia and lung cancer in the Linxian General Population Trial cohort. Method: The Linxian General Population Trial cohort, with 29,584 healthy adults enrolled in 1985 and followed through the end of 2012. With collected baseline data, hazard ratios (HR) and 95% confidence intervals (95% CI) for developing lung cancer were estimated using Cox proportional hazard models. Results: Overall, a total of 29449 were included in the final analysis. During 28 years of follow up, we confirmed a total of 277 incident lung cancer cases. Overall, participants with oral leukoplakia had little risk for developing lung cancer (HR¼1.01, 95%CI: 0.67, 1.16). No significant associations were observed for lung cancer in either all subjects or subgroups. Conclusion: Our results suggest that oral leukoplakia is not associated with increased risk of lung cancer mortality. Future studies are needed to confirm these findings. (NSCLC). Based on the characteristic pattern of response and progression, however, there is substantial clinical concern about the timing of switching treatment after progressive disease in patients receiving nivolumab treatment. Method: We conducted a consecutive retrospective analysis of patients with advanced NSCLC treated with nivolumab as a second-line treatment at the National Cancer Center Hospital from December 2015 to November 2017. Clinical information including age, sex, performance status (PS), histology, and progressive disease (PD) situation at the point of the last dose of nivolumab were evaluated. We defined the PD situation as follows: continuation of nivolumab after worsening of imaging findings (beyond PD); PD after &2 cycles of nivolumab without beyond PD (Early PD), and PD after 3S cycles of nivolumab without beyond PD as (Late PD). Results: A total of 213 patients received nivolumab; 109 of these patients received nivolumab as a second-line treatment. Finally, 105 patients (78 men, 27 women) without EGFR or ALK driver oncogene mutations were included in this analysis. The patients' characteristics were as follows: male/female, 78/27 patients; median age (range), 63 (34-83) years; PS 0/1/2/3/4, 19/57/18/6/5 patients; and non-squamous/ squamous histology, 77/28 patients. Four patients were treated beyond PD. The median number of nivolumab treatment cycles was 6, the objective response rate was 16%, and the median progressionfree survival was 3.9 months (95% confidence interval: 2.5-6.0 months). Among the 90 patients with disease progression, 42 patients (47%) received chemotherapy after nivolumab treatment. Among the patients with disease progression who did not receive chemotherapy after nivolumab treatment (48 patients, 53%), the main reasons for non-administration were a worsening of the patient's condition after beyond PD, (n ¼ 4, 8%),late PD, (n ¼ 11, 23%), early PD, (n ¼ 21, 44%), adverse events associated with nivolumab treatment, (n ¼ 6, 13%), patient's preference (n ¼ 3, 6%),and unknown (n ¼ 3, 6%). Conclusion: The administration of nivolumab beyond PD accounted for 8% of the reasons for not receiving subsequent chemotherapy. Background: To evaluate the feasibility and safety of sleeve lobectomy for centrally located non-small cell lung cancer and summarize our surgical experience. Method: Clinical data of 45 patients who underwent sleeve lobectomy at Department of Thoracic Surgery of Liaoning Cancer Hospital & Institute from November 2016 to June 2018 including 6 cases had neoadjuvant chemotherapy were collected retrospectively, and operative strategies, time of postoperative drainage, postoperative hospital stay and postoperative complications were also recorded. Results: All patients received sleeve lobectomy successfully. Of all the patients, 8 patients underwent bronchial and arterial sleeve lobectomy, 4 underwent bronchial sleeve resection and partial side wall of arterial resection, 2 underwent arterial sleeve resection and partial side wall of bronchial resection, 31 underwent bronchial sleeve resection only. There was no perioperative death in all patients. Margin status was R0 in 39 patients (86.7%), R1 in 5 patients (11.1%), R2 in 1 patient (2.2%). The median time of postoperative drainage was 7 days (3-26 days), median time of postoperative hospital stay was 11 days (6-28 days). Major complications occurred in 11 patients (24.4%), including 1 chylothorax, 6 pneumonia, 3 pleural effusion, 1 air leak. Endotracheal endoscopic sputum aspiration was performed in 11 patients postoperatively. Pathologic diagnosis showed squamous cell carcinoma in 35 patients, adenocarcinoma in 6 patients, adenosquamous carcinoma in 2 patients, and large cell carcinoma in 1 patient. 2 patients were in stage ⅠA3, 7 patients were in stage ⅠB, 2 patients were in stage ⅡA, 24 patients were in stage ⅡB, 5 patients were in stage ⅢA，and 4 patients were in stage ⅢB. All patients recovered well and were discharged uneventfully. Conclusion: Sleeve lobectomy is a safe and feasible procedure for treatment of centrally located non-small-cell lung cancer. It is an accepted procedure to expand operation indications and avoid pneumonectomy, improve postoperative quality of life.
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